#China #Shanghai #Denosumab #Mabwell #MAIWEIJIAN

Mabwell's MAIWEIJIAN: A Step Forward in Biopharmaceuticals

Mabwell, an innovative biopharmaceutical company based in Shanghai, is making waves in the medical community with its groundbreaking product, MAIWEIJIAN (denosumab injection, RD code 9MW0321). Recently, the National Medical Products Administration (NMPA) has accepted the application for a supplemental Biologics License, a significant step in the journey for MAIWEIJIAN. This acceptance is pivotal as it allows for the prevention of skeletal-related events (SREs) in patients battling multiple myeloma and those with bone metastases from solid tumors.

The Importance of MAIWEIJIAN

As the first denosumab biosimilar approved for sale in China, MAIWEIJIAN holds a unique position. Originally approved in March 2024, this injectable treatment was designed for adults and skeletally mature adolescents suffering from unresectable giant cell tumors of the bone, or when surgery poses a risk of significant morbidity. Following its success, the product also received approval for the same use in Pakistan in August 2025, further expanding its reach in the global market.

Mabwell’s journey with MAIWEIJIAN reflects its commitment to improving patient outcomes and expanding treatment options. The company has formal agreements for production and distribution in 33 countries, including major markets like Brazil, Saudi Arabia, and Indonesia. In addition, plant trials are underway in eight more countries, underlining the global potential of this innovative treatment.

Understanding Denosumab

Denosumab, the active ingredient within MAIWEIJIAN, has garnered recognition for its efficacy in combating certain types of cancer-related bone degradation. Unlike traditional bisphosphonates, which have long been the standard treatment, denosumab offers several advantages. It targets the RANKL (Receptor Activator of Nuclear factor Kappa-Β Ligand) directly, disrupting the osteoclast-mediated bone resorption that leads to critical complications in cancer patients.

Additionally, clinical studies reveal that denosumab is associated with superior efficacy compared to bisphosphonates, including patients who have not responded to prior bisphosphonate therapies. Another notable point is its favorable safety profile; patients receiving denosumab experience fewer side effects related to renal function, making it a safer option for those facing kidney concerns.

Clinical Validation

Mabwell’s rigorous clinical study results have already been published in reputable journals such as International Immunopharmacology and JAMA Oncology. These studies showcased pharmacokinetic and pharmacodynamic similarities to the reference product, ensuring that MAIWEIJIAN is an effective option for managing bone metastasis and other cancers.

The Future of Mabwell

Positioning itself for growth, Mabwell's philosophy revolves around transforming innovative ideas into healthcare solutions. With a mission to address global health challenges in oncology and age-related diseases, the company’s vision supports its slogan “Explore Life, Benefit Health.” As MAIWEIJIAN continues to gain international traction, Mabwell remains focused on expanding its portfolio in the biopharmaceutical sector.

As the realm of biopharmaceuticals evolves, products like MAIWEIJIAN not only signal advancements in research and development but also the potential for improved outcomes in patient care globally. The acceptance of the supplemental Biologics License Application by NMPA marks a significant milestone, one that propels Mabwell to the forefront of the industry and provides renewed hope for patients worldwide.

For more information on Mabwell and its transformative products, visit Mabwell's official website.